Clinical Trials on T Cell Non-Hodgkin Lymphoma

Total 14748 results

Stanford University
National Institutes of Health (NIH); Amgen

Completed

Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment

Lymphoma, Non-Hodgkin | Lymphomas: Non-Hodgkin | Lymphomas: Non-Hodgkin Peripheral T-Cell | Lymphomas: Non-Hodgkin Cutaneous Lymphoma | Lymphomas: Non-Hodgkin Diffuse Large B-Cell | Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell | Lymphomas: Non-Hodgkin Mantle Cell | Lymphomas: Non-Hodgkin Marginal... and other conditions

United States
John Reneau

Recruiting

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Recurrent Adult T-Cell Leukemia/Lymphoma | Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Refractory Adult T-Cell Leukemia/Lymphoma

United States
National Cancer Institute (NCI)

Terminated

O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma

Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma | Stage I Cutaneous T-cell Non-Hodgkin Lymphoma | Stage II Cutaneous T-cell Non-Hodgkin Lymphoma

United States
Peking Union Medical College Hospital
Peking University First Hospital; Chinese PLA General Hospital; Peking University... and other collaborators

Recruiting

Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma

T Cell Non-Hodgkin's Lymphoma

China
Keimyung University Dongsan Medical Center
Otsuka Pharmaceutical Co., Ltd.

Recruiting

Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas (RRTCLAlloSCT)

Lymphoma, Extranodal NK-T-Cell | T-cell Non-Hodgkin Lymphoma

Korea, Republic of
John Reneau

Active, not recruiting

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma | Primary Cutaneous Anaplastic Large Cell Lymphoma | Refractory Primary Cutaneous T-Cell Non-Hodgkin... and other conditions

United States
Peking University People's Hospital

Not yet recruiting

CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma

T-cell Non-Hodgkin's Lymphoma
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma

United States
Autolus Limited

Recruiting

Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma

Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | T Cell Non-Hodgkin Lymphoma | Peripheral T-Cell Lymphoma, Not Otherwise Specified

United Kingdom, Spain
Celgene

Terminated

A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma (EXPECT)

T-cell Non-Hodgkin's Lymphoma

France, United States, Australia, Belgium
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

Sezary Syndrome | Recurrent Mycosis Fungoides | Refractory Mycosis Fungoides | Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma | Folliculotropic Mycosis Fungoides | Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified | Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma | Refractory Cutaneous...

United States
Arbeitsgemeinschaft medikamentoese Tumortherapie
Merck Sharp & Dohme LLC; Celgene Corporation

Terminated

Lenalidomide, Vorinostat and Dexamethasone in Relapsed Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL) (LenVoDex)

Peripheral T-Cell Non-Hodgkin's Lymphoma

Austria
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma

Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma | Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma | Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma

United States
Memorial Sloan Kettering Cancer Center
Weill Medical College of Cornell University; University of Washington; H. Lee...

Active, not recruiting

A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma

T Cell Non-Hodgkin Lymphoma

United States
Dana-Farber Cancer Institute
Novartis; Brigham and Women's Hospital

Completed

Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma

T Cell Non-Hodgkin Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma

Anaplastic Large Cell Lymphoma | Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma

United States
Institute of Hematology & Blood Diseases Hospital
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Beijing...

Unknown

γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkin's Lymphoma | Peripheral T Cell Lymphoma | Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma | Chronic Lymphoblastic Leukemia

China
AHS Cancer Control Alberta
Alberta Cancer Foundation; Celgene Corporation

Completed

A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma

T-cell Lymphoma

Canada
National Cancer Institute (NCI)

Completed

506U78 in Treating Patients With Lymphoma

Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Recurrent Adult T-cell Leukemia/Lymphoma | Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides/Sezary Syndrome | Small Intestine Lymphoma | Stage III Cutaneous T-cell Non-Hodgkin Lymphoma | Stage III Mycosis... and other conditions

United States
Stanford University

Terminated

Phase 2 Total Skin Electron Beam Therapy (TSEBT 12 Gy) in Stage IB-IIIA Mycosis Fungoides

Mycosis Fungoides | Lymphomas: Non-Hodgkin | Lymphomas: Non-Hodgkin Peripheral T-Cell | Lymphomas: Non-Hodgkin Cutaneous Lymphoma

United States
Mundipharma Research Limited
Innovative Therapies For Children with Cancer Consortium

Terminated

Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma. (BCX1777-108)

Relapsed or Refractory T-cell Acute Lymphoblastic Leukaemia | B-cell Precursor Acute Lymphoblastic Leukaemia | T-cell Non-Hodgkin's Lymphoma

Czech Republic, Austria, France, Germany, Italy, United Kingdom
National Cancer Institute (NCI)

Recruiting

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous... and other conditions

United States
Samsung Medical Center
Janssen Medical Affairs

Completed

Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas

Non-Hodgkin Lymphoma | Peripheral T-Cell Lymphomas

Korea, Republic of
National Cancer Institute (NCI)

Completed

Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma

Anaplastic Large Cell Lymphoma | Recurrent Adult Non-Hodgkin Lymphoma | Angioimmunoblastic T-Cell Lymphoma | Hepatosplenic T-Cell Lymphoma | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Recurrent Adult T-Cell Leukemia/Lymphoma | Adult Nasal Type Extranodal NK/T-Cell Lymphoma

United States, Canada
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.

Recruiting

Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies (CD5CAR-T)

T-cell Acute Lymphoblastic Leukemia | T-cell Non-Hodgkin Lymphoma

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

Recurrent Angioimmunoblastic T-Cell Lymphoma | Recurrent Mycosis Fungoides | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Refractory Angioimmunoblastic T-Cell Lymphoma | Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Refractory Mycosis Fungoides | Refractory Anaplastic... and other conditions

United States
SCRI Development Innovations, LLC
Infinity Pharmaceuticals, Inc.

Completed

Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies

Lymphoma | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | T-cell Lymphoma

United States
TG Therapeutics, Inc.
SCRI Development Innovations, LLC

Completed

Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia | Peripheral T-Cell Lymphoma

United States
The University of Hong Kong

Unknown

SIMPLE Chemotherapy for NK Lymphoma/Leukaemia

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin T-cell Lymphoma

Hong Kong
Walter Hanel

Active, not recruiting

Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas

Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Refractory Anaplastic Large Cell Lymphoma | T-Cell Non-Hodgkin Lymphoma | Refractory Primary Cutaneous T-Cell Non-Hodgkin... and other conditions

United States
Seagen Inc.
Bristol-Myers Squibb

Completed

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

Hodgkin Disease | Peripheral T Cell Lymphoma

United States, Canada
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | Adult Diffuse Large B-Cell Lymphoma | T-Cell Non-Hodgkin Lymphoma

United States
Fundamenta Therapeutics, Ltd.
The First Affiliated Hospital of University of Science and Technology of...

Recruiting

Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies

T-Acute Lymphoblastic Leukemia | T-cell Non-Hodgkin Lymphoma | T-cell Acute Lymphoblastic Lymphoma

China
AstraZeneca

Completed

AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL

Relapsed/Refractory Peripheral T-cell Lymphoma | Relapsed/Refractory Classical Hodgkins Lymphoma

Italy, Sweden, United States, Taiwan, Korea, Republic of, United Kingdom, Australia, France, Singapore
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

Refractory Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Completed

Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Splenic Marginal Zone Lymphoma | Anaplastic Large Cell Lymphoma | Recurrent Adult Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent... and other conditions

United States
City of Hope Medical Center

Withdrawn

Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas

Sezary Syndrome | Recurrent Mycosis Fungoides | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Refractory Mycosis Fungoides | Folliculotropic Mycosis Fungoides | CD30-Positive Neoplastic Cells Present | Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

United States
Wuhan Union Hospital, China
Beijing GoBroad Hospital Management Co.,Ltd; Shanghai YaKe Biotechnology Ltd.

Recruiting

Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies

T-Cell Lymphocytic Leukemia | T-Cell Chronic Lymphocytic Leukemia | T Cell Non-Hodgkin Lymphoma

China
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Recruiting

CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma

Non Hodgkin Lymphoma | Relapsed T-Cell Lymphoma | Refractory T-Cell Lymphoma

United States
M.D. Anderson Cancer Center

Active, not recruiting

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides | Refractory Mycosis Fungoides | Recurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma | Refractory Anaplastic Large Cell Lymphoma | Recurrent Anaplastic Large Cell Lymphoma and other conditions

United States
Vittoria Biotherapeutics
University of Pennsylvania

Not yet recruiting

CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL) (VIPER101)

T Cell Non-Hodgkin Lymphoma

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Peripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Hepatosplenic T-cell Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Adult Hodgkin Lymphoma | Recurrent Adult T-cell Leukemia/Lymphoma and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Hematopoietic Cell Transplantation Recipient

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Recruiting

Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA)

T-cell Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Lymphoma | T-non-Hodgkin Lymphoma

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma

Lymphoma

United States
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.

Recruiting

Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances

T-cell Acute Lymphoblastic Leukemia | T-cell Non-Hodgkin Lymphoma | T-cell Acute Lymphoblastic Lymphoma

China
Estrella Biopharma, Inc.
Eureka Therapeutics Inc.

Not yet recruiting

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (Starlight-1)

Lymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
National Cancer Institute (NCI)

Active, not recruiting

Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular Lymphoma | Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides | Recurrent Primary Cutaneous... and other conditions

United States, Canada
National Cancer Institute (NCI)

Terminated

Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides

Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides/Sezary Syndrome | Stage III Cutaneous T-cell Non-Hodgkin Lymphoma | Stage III Mycosis Fungoides/Sezary Syndrome | Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma | Stage IV Mycosis Fungoides/Sezary Syndrome | Stage I... and other conditions

United States

Clinical Trials on T Cell Non-Hodgkin Lymphoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations